News

The newly issued patents are assigned to VIVUS and will be submitted for listing in the FDA’s Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book) and

PACF partners with local organisations working to improve the health and wellbeing of women and children affected by HIV, and the communities they live in. All PACF projects

The move is claimed to be the first time in North America that people have been treated with the narcotic after being part of a clinical research trial,

Recipharm will significantly expand its pharmaceutical development capacity and technical capabilities to provide easier access for development services to its French and other customers. Recipharm will also provide

Vargatef in combination with docetaxel is approved for use in adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology,

At present, Dynavax has global rights to continue the development of DV1179 and other TLR 7/9 inhibitors for all indications. As part of the deal, Dynavax carried out

In consideration for the Technology, the Company paid to Ms. Arnett and Mr. Hargreaves a total of USD $100,000 and issued to Ms. Arnett and Mr. Hargreaves options

Recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are

The CDP was prepared in collaboration with d3 Medicine and contains detailed plans for all pre-clinical tasks including pharmacology, pharmacokinetics, manufacturing, formulation and toxicology of MetaMx. Arch Biopartners